Wednesday, December 03, 2025

 

Americans more likely to accept guidance from AMA than CDC on vaccine safety





Annenberg Public Policy Center of the University of Pennsylvania

When vaccine safety recommendations conflict: Acceptance of AMA and CDC recommendations 

image: 

The percentage of the public that would be likely to accept the recommendations on vaccine safety of the Centers for Disease Control and Prevention (CDC) and the American Medical Association (AMA), including breakdowns by political party identification and age. Source: Annenberg Public Policy Center, from the SSRS Omnibus Survey Nov. 21-24, 2025. 

view more 

Credit: Annenberg Public Policy Center





PHILADELPHIA – For decades, health-related statements by major professional health associations such as the American Medical Association (AMA) agreed with those of the Centers for Disease Control and Prevention (CDC) because both relied on the same body of scientific knowledge, much of it funded by the federal health sector. However, the public can no longer assume that the CDC and major public health organizations are on the same page. 

In late November 2025, for example, when the CDC website legitimized the discredited link between vaccination and autism, mainstream professional health organizations condemned the changes. Fueling the outcry were two additions to the CDC website, under the leadership of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. The first declared that “the claim ‘vaccines do not cause autism’ is not an evidence-based claim because studies have not ruled out the possibility that infant vaccines cause autism.” The second alleged that “studies supporting a link have been ignored by health authorities.” These claims now appear as the first two key points in a box at the beginning of the CDC’s Autism and Vaccines page.

“Despite recent changes to the CDC website, an abundance of evidence from decades of scientific studies shows no link between vaccines and autism,” declared an AMA statement. Casting the changes as “reckless and harmful,” the Infectious Diseases Society of America argued that “this change is not driven by science but by politics and will only serve to increase mistrust in science and medicine.” The president of the American Academy of Pediatrics called on the CDC to remove the false information and “stop wasting government resources to amplify false claims …”

To determine what the public is making of the controversy, the Annenberg Public Policy Center (APPC) of the University of Pennsylvania engaged SSRS to survey a nationally representative sample of 1,006 adults online from November 21-24, 2025. The survey has a margin of error of ±3.4 percentage points at the 95% confidence level. The survey, created by APPC’s Annenberg Health and Risk Communication Institute (AHRCI), asks about the public’s confidence that the CDC is providing trustworthy information about the safety and effectiveness of vaccines, how people react to conflicting cues about vaccine safety from the AMA and the CDC, and public views about whether vaccines and autism are linked.

The Annenberg survey finds that:

  • By a 2-1 margin, the public would be more likely to accept the AMA’s recommendation on vaccine safety (35%) than the CDC’s (16%) if the two bodies issue conflicting advice;
  • Regardless of party, Americans would accept the AMA’s recommendations on vaccine safety over the CDC’s;
  • Half of older Americans age 65+ (50%) would be more likely to accept the AMA’s recommendations on vaccine safety over the CDC’s (13%); the only age group more likely to accept the CDC over the AMA are 18- to 29-year-olds, by 24% to 19%.

Download the survey topline.

When the CDC and AMA conflict on vaccine safety

If the CDC and the AMA gave conflicting recommendations on the safety of a vaccine, Americans say they would be more likely to accept the recommendation of the AMA by a 2 to 1 margin over the CDC: 35% say they would take the recommendation of the AMA, while just 16% would take the recommendation of the CDC. In addition, 21% say they would take neither organization’s recommendation and 27% say they are not sure.

Party differences: Regardless of party, Americans would accept the AMA’s recommendations on vaccine safety over the CDC’s. More than 4 in 10 (43%) self-identified Democrats say they would accept the AMA’s recommendation regarding the safety of a vaccine, while 18% would accept the CDC’s. Three in 10 (31%) self-identified Republicans indicate that they are more likely to accept the AMA’s recommendation over the CDC’s (13%). Similarly, among self-identified independents or those in other parties, 31% would accept the AMA recommendation, compared with 18% who say they would take the CDC’s.

When faced with differing recommendations about the safety of a vaccine, Republicans are more skeptical of both the AMA and CDC, compared with Democrats and independents. A third (32%) of Republicans say they would take neither organization’s recommendation, compared with 8% of Democrats and 23% of independents.

“Political party differences here are not surprising,” said Ken Winneg, APPC’s managing director of survey research. “The different willingness to rely on the AMA vs. the CDC, based on political party, is consistent with research showing that partisanship is now a clear factor in health perceptions. But it’s important to note that most independents, Democrats, and Republicans would accept an AMA recommendation over a CDC one about vaccine safety.”

Age differences: Half of U.S. adults age 65 and older (50%) are more likely to take the AMA’s guidance on vaccines than the CDC’s (13%). However, younger adults 18 to 29 are statistically just as likely to say they would accept the recommendation of the CDC as the AMA’s on vaccine safety. Nearly a quarter (24%) of those 18 to 29 would go with the CDC’s recommendation and about 1 in 5 (19%) would take the AMA’s. Similar to other age groups, most young people say they would take neither organization’s recommendation (20%) though more say they are not sure (37%). A greater proportion in each of the other age groups would clearly pick the AMA’s recommendation on vaccine safety over the CDC’s (32% AMA vs. 18% CDC among 30 to 49-year-olds; and 36% AMA vs. 12% CDC among 50 to 64-year-olds).

Just over half say CDC providing trustworthy information on vaccines

Just over half of adults (52%) are confident that the CDC is providing the public with trustworthy information about the safety and effectiveness of vaccines. Just 16% are very confident and 36% are somewhat confident. One in five (21%) are not at all confident in the CDC and 27% are not too confident. There are no significant differences in overall confidence by party or gender.

Younger people age 18 to 29 are more likely to say they are confident in the CDC on vaccine safety and effectiveness (59%) than adults 65 and older (47%).

CDC’s prior advice on vaccines aligns better with public’s view than today’s advice

Until November 20, 2025, the CDC’s website said, “Studies have shown that there is no link between receiving vaccines and developing autism.” Then the website was revised to say, “The claim ‘vaccines do not cause autism’ is not an evidence-based claim because studies have not ruled out the possibility that infant vaccines cause autism.” When asked which of these two statements about vaccines and autism comes closer to their own views, a narrow majority (52%) chooses the statement saying there is no link between vaccines and autism. Nearly a third (30%), however, say their views are closer to the latest statement by the CDC that “the claim that ‘vaccines do not cause autism’ is not an evidence-based claim because studies have not ruled out the possibility that infant vaccines cause autism.” Eighteen percent (18%) say they are not sure.

Party differences: There are significant differences by political party identification in acceptance of the debunked autism-vaccination link. Democrats (74%) and independents (52%) are significantly more likely than Republicans (33%) to endorse the view that there is no link between receiving a vaccine and autism. Nearly half of Republicans (48%) say that the claim is not evidence-based, over three times more than Democrats (14%). Independents are between those groups: about 3 in 10 (27%) say they are closer to the view that the vaccine-autism link has not been ruled out.

Young adults 18 to 29 years old are more likely than older adults to hold the view that there is no link between receiving a vaccine and autism. Nearly 7 in 10 (68%) adults age 18 to 29 say there is no link, compared with 48% of those age 30 to 49, 44% of those age 50 to 64, and 55% of those age 65 or older.

Most people unsure what CDC website now says on vaccines and autism

In a follow-up question, APPC researchers asked survey respondents which of the two statements noted above about vaccines and autism is currently on the CDC website. Most people (50%) say they are not sure which statement is on the website. The others are split, with 19% incorrectly saying the “no link” statement is currently on the site, and 20% correctly saying the “studies have not ruled out the possibility [of autism]” statement is on the site. Small groups say that both statements (7%) are on the site or that neither is on the site (4%).

“A possible source of confusion,” said Patrick E. Jamieson, director of APPC’s Annenberg Health and Risk Communication Institute, “is the continuing presence on the CDC site of the header ‘Vaccines do not cause autism’ which, according to an asterisk linked to it, ‘has not been removed due to an agreement with the chair of the U.S. Senate Health, Education, Labor, and Pensions Committee that it would remain on the CDC website.’ This crafty move has honored the letter but not the spirit of HHS Secretary Robert F. Kennedy Jr.’s pledge to Senator Bill Cassidy (R., LA) that the CDC would not ‘remove statements on their website pointing out that vaccines no not cause autism.’ ”

Regardless of party identification, the most common response is that people are unsure which statement is on the CDC website, with 57% of Republicans, 43% of Democrats, and 50% of independents reporting that they are not sure. The remainder are generally split over which statement is on the site.

Decline in belief that vaccines are not linked to autism

A science-consistent public understanding about vaccinated and unvaccinated children and autism had been declining before Robert F. Kennedy Jr. became HHS Secretary and before these CDC website changes were made.

In April 2021, nearly four years before Kennedy became Health Secretary, APPC began tracking the public’s understanding about vaccinated and unvaccinated children and autism. Since that time, there has been a decline in the proportion of people who say the claim “that increased vaccinations are why so many kids have autism these days” is false. In April 2021, 71% said the statement was false, but that number dropped significantly to 65% in October 2023, two and a half years later. Similarly, the number who believe the statement to be true increased significantly over that time period, from 10% and 11% in April and June 2021, respectively, to 16% in October 2023.

“Even before Covid-19, our survey data were showing an increase in those who believe that either a particular vaccine or the number of childhood vaccinations cause autism,” said Laura A. Gibson, an APPC research analyst. “If that sentiment leads to fewer life-saving vaccinations, there may be tragic consequences for some children and communities.”

Nearly half (47%) of those surveyed report believing that children who are fully vaccinated are about as likely to show signs of autism as children who are not fully vaccinated. The public is evenly divided on whether fully vaccinated children are more likely (12%) or less likely (12%) to show signs of autism. Nearly 3 in 10 people (29%) are not sure.

Democrats (57%) and independents (47%) are also more likely than Republicans (38%) to say fully vaccinated children are just as likely as children who are not vaccinated to show signs of autism. Nearly a quarter (23%) of Republicans say fully vaccinated children are more likely to show signs of autism, which is nearly six times more than Democrats (4%). Independents are between those groups, at 9%.

Methodology

Data from the survey come from a nationally representative sample of 1,006 U.S. adults, conducted for the Annenberg Public Policy Center by SSRS, an independent market research company.

The sample was drawn from SSRS’s probability based online opinion panel and was fielded November 21-24, 2025, and has a margin of sampling error (MOE) of ± 3.4 percentage points at the 95% confidence level. All figures are rounded to the nearest whole number and may not add to 100%. Combined subcategories may not add to totals in the topline and text due to rounding.

Download the topline and methodology report.

The policy center has been tracking the American public’s knowledge, beliefs, and behaviors regarding vaccination, Covid-19, flu, RSV, and other consequential health issues through the Annenberg Science and Public Health (ASAPH) and separate national samples since April 2021. APPC’s health survey team includes Ken Winneg, managing director of survey research, research analyst Laura A. Gibson, and Patrick E. Jamieson, director of the Annenberg Health and Risk Communication Institute.

See other recent Annenberg health survey news releases:

The Annenberg Public Policy Center was established in 1993 to educate the public and policy makers about communication’s role in advancing public understanding of political, science, and health issues at the local, state, and federal levels.

  

The graphic shows the decrease in the percentage of people who believe it is false to say that "increased vaccinations are why so many kids have autism these days." The change from April 2021 (71%) to October 2023 (65%) is statistically sigificant. Source: Annenberg Science and Public Health surveys from the Annenberg Public Policy Center.

Credit

Annenberg Public Policy Center

 

How two Russian scientists changed the way we understand aging and cancer



“Here, conceptual similarities between Mikhail Blagosklonny’s hyperfunction theory of aging and Vladimir Dilman’s elevation theory of aging are considered”



Impact Journals LLC

On the intergenerational transfer of ideas in aging and cancer research: from the hypothalamus according to V.M. Dilman to the mTOR protein complex according to M.V. Blagosklonny 

image: 

Figure 1. Professor V.M. Dilman

view more 

Credit: Copyright: © 2025 Golubev et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




“Here, conceptual similarities between Mikhail Blagosklonny’s hyperfunction theory of aging and Vladimir Dilman’s elevation theory of aging are considered.”

BUFFALO, NY — December 3, 2025 — A new essay was published in Volume 17, Issue 11 of Aging-US on November 19, 2025, titled “On the intergenerational transfer of ideas in aging and cancer research: from the hypothalamus according to V.M. Dilman to the mTOR protein complex according to M.V. Blagosklonny.

In this work, Aleksei G. Golubev from the N.N. Petrov National Medical Research Center of Oncology reflects on the legacy of two influential Russian scientists, Vladimir M. Dilman and his son Mikhail V. Blagosklonny, who each introduced groundbreaking ideas about aging and cancer. Drawing from his own experience working in Professor Dilman’s lab, Golubev explores how their ideas remain deeply relevant to today’s scientific understanding.

The essay connects Professor Dilman’s “elevation theory” with Dr. Blagosklonny’s “hyperfunction theory,” two frameworks that challenge the conventional view of aging as a process of decline. Instead, both propose that aging results from continued biological processes that once supported growth but eventually become harmful when left unchecked.

Professor Dilman believed that aging begins with reduced sensitivity in the hypothalamus, a brain region that regulates the body’s balance. This desensitization disrupts metabolism and hormone levels, setting the stage for many chronic illnesses. Decades later, Dr. Blagosklonny expanded on this idea at the molecular level. Central to his theory is the mTOR protein complex, which regulates growth and metabolism and is now a major focus in aging research.

Golubev also explores the historical and personal connections between the two scientists. Professor Dilman, an endocrinologist trained in the Soviet Union, and Dr. Blagosklonny, a molecular biologist educated during the post-Soviet period, represent two generations shaped by a shared scientific tradition. 

“Dilman’s scientific legacy is not as well recognized as it should be, partly due to bias in citation practices.”

The essay also draws attention to a troubling trend in science: the tendency to overlook early contributions, especially from non-Western scholars. Many of Professor Dilman’s insights, such as the connection between high blood sugar, insulin resistance, and cancer, have since been validated by modern tools, yet his work is rarely cited. Golubev points out how citation practices, language barriers, and historical isolation have contributed to this lack of recognition.

Finally, Golubev encourages the scientific community to look back and acknowledge the foundational work that shaped modern aging science. It also highlights the importance of cross-generational knowledge in moving science forward. By tracing the intellectual journey from hormonal regulation in the brain to molecular pathways in cells, this essay demonstrated the relevance of old ideas in a new biological era.

Paper DOIhttps://doi.org/10.18632/aging.206338

Corresponding author: Aleksei G. Golubev – lxglbv@rambler.ru

Abstract video: https://www.youtube.com/watch?v=LvrdghTKGws

Keywords: aging, gerontology, history of science, hyperfunction, mTOR, hypothalamus, cancer, metabolism, immunity.

Click here to sign up for free Altmetric alerts about this article.

______

To learn more about the journal, please visit www.Aging-US.com​​ and connect with us on social media:

Click here to subscribe to Aging-US publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Noninvasive imaging could replace finger pricks for people with diabetes



MIT engineers have shown they can accurately measure blood glucose levels by shining near-infrared light on the skin


Massachusetts Institute of Technology

Noninvasive blood-glucose monitoring method 

image: 

 

A noninvasive blood-glucose monitoring method developed at MIT could spare diabetes patients from frequent finger pricks and potentially replace traditional monitoring devices.

view more 

Credit: Christine Daniloff/MIT




CAMBRIDGE, MA -- A noninvasive method for measuring blood glucose levels, developed at MIT, could save diabetes patients from having to prick their fingers several times a day.

The MIT team used Raman spectroscopy — a technique that reveals the chemical composition of tissues by shining near-infrared or visible light on them — to develop a shoebox-sized device that can measure blood glucose levels without any needles.

In tests in a healthy volunteer, the researchers found that the measurements from their device were similar to those obtained by commercial continuous glucose monitoring sensors that require a wire to be implanted under the skin. While the device presented in this study is too large to be used as a wearable sensor, the researchers have since developed a wearable version that they are now testing in a small clinical study.

“For a long time, the finger stick has been the standard method for measuring blood sugar, but nobody wants to prick their finger every day, multiple times a day. Naturally, many diabetic patients are under-testing their blood glucose levels, which can cause serious complications,” says Jeon Woong Kang, an MIT research scientist and the senior author of the study. “If we can make a noninvasive glucose monitor with high accuracy, then almost everyone with diabetes will benefit from this new technology.”

MIT postdoc Arianna Bresci is the lead author of the new study, which appears today in the journal Analytical Chemistry.  Other authors include Peter So, director of the MIT Laser Biomedical Research Center (LBRC) and an MIT professor of biological engineering and mechanical engineering, and Youngkyu Kim and Miyeon Jue of Apollon Inc., a biotechnology company based in South Korea.

Noninvasive glucose measurement

While most diabetes patients measure their blood glucose levels by drawing blood and testing it with a glucometer, some use wearable monitors, which have a sensor that is inserted just under the skin. These sensors provide continuous glucose measurements from the interstitial fluid, but they can cause skin irritation and they need to be replaced every 10 to 15 days.

In hopes of creating wearable glucose monitors that would be more comfortable for patients, researchers in MIT’s LBRC have been pursuing noninvasive sensors based on Raman spectroscopy. This type of spectroscopy reveals the chemical composition of tissue or cells by analyzing how near-infrared light is scattered, or deflected, as it encounters different kinds of molecules.

In 2010, researchers at the LBRC showed that they could indirectly calculate glucose levels based on a comparison between Raman signals from the interstitial fluid that bathes skin cells and a reference measurement of blood glucose levels. While this approach produced reliable measurements, it wasn’t practical for translating to a glucose monitor.

More recently, the researchers reported a breakthrough that allowed them to directly measure glucose Raman signals from the skin. Normally, this glucose signal is too small to pick out from all of the other signals generated by molecules in tissue. The MIT team found a way to filter out much of the unwanted signal by shining near-infrared light onto the skin at a different angle from which they collected the resulting Raman signal.

The researchers obtained those measurements using equipment that was around the size of a desktop printer, and since then, they have been working on further shrinking the footprint of the device.

In their new study, they were able to create a smaller device by analyzing just three bands — spectral regions that correspond to specific molecular features — in the Raman spectrum.

Typically, a Raman spectrum may contain about 1,000 bands. However, the MIT team found that they could determine blood glucose levels by measuring just three bands — one from the glucose plus two background measurements. This approach allowed the researchers to reduce the amount and cost of equipment needed, allowing them to perform the measurement with a cost-effective device about the size of a shoebox.

“By refraining from acquiring the whole spectrum, which has a lot of redundant information, we go down to three bands selected from about 1,000,” Bresci says. “With this new approach, we can change the components commonly used in Raman-based devices, and save space, time and cost.”

Toward a wearable sensor

In a clinical study performed at the MIT Center for Clinical Translation Research (CCTR), the researchers used the new device to take readings from a healthy volunteer over a four-hour period. As the subject rested their arm on top of the device, a near-infrared beam shone through a small glass window onto the skin to perform the measurement.

Each measurement takes a little more than 30 seconds, and the researchers took a new reading every five minutes.

During the study, the subject consumed two 75-gram glucose drinks, allowing the researchers to monitor significant changes in blood glucose concentration. They found that the Raman-based device showed accuracy levels similar to those of two commercially available, invasive glucose monitors worn by the subject.

Since finishing that study, the researchers have developed a smaller prototype, about the size of an iPhone, that they are currently testing at the MIT CCTR as a wearable monitor in healthy and prediabetic volunteers. Next year, they plan to run a larger study working with a local hospital, which will include people with diabetes.

The researchers are also working on making the device even smaller, about the size of a watch. Additionally, they are exploring ways to ensure that the device can obtain accurate readings from people with different skin tones.

###

The research was funded by the National Institutes of Health, the Korean Technology and Information Promotion Agency for SMEs, and Apollon Inc.

The MIT team used Raman spectroscopy — a technique that reveals the chemical composition of tissues by shining near-infrared or visible light on them — to develop a shoebox-sized device that can measure blood glucose levels without using any needles.

Credit

MIT

 CANADA

Algoma Steel to cease blast furnace operations, lay off 1,000 workers as tariffs bite

Credit: Algoma Steel

Canadian steelmaker Algoma Steel said on Monday it would lay off 1,000 employees and close its blast furnace and coke-making operations in Ontario in early 2026 due to tariff pressures.

The Trump administration’s 50% tariffs on foreign steel have significantly restricted access for Canadian producers to the US market.

Algoma, based in Sault Ste. Marie, added it will transition to steelmaking by electric arc furnace in early 2026, a year earlier than previously planned.

The North American steel market is highly integrated, and Algoma Steel has been significantly impacted by the unprecedented tariffs imposed by the US, the company said.

The company had reported direct tariff costs of C$89.7 million ($64.10 million) for the three months ended September 30, with shipments to the US representing about half of total steel volumes.

Algoma will issue about 1,000 layoff notices which will be effective on March 23, 2026. As of December 31, 2024, the company had 2,818 full-time employees.

“This transition is necessary to protect Algoma’s future in the face of these extraordinary and external market forces,” the company said.

($1 = 1.3994 Canadian dollars)

(By Pranav Mathur; Editing by Krishna Chandra Eluri and Maju Samuel)

 

Spain Rescues Aging Freighter Left Adrift Without Fuel

Marine I
Marine I under way in better times, 2017 (file image courtesy Cengiz Tokgoz / VesselFinder)

Published Nov 30, 2025 6:22 PM by The Maritime Executive

 

Spanish maritime authorities have decided to tow a ship that had allegedly been abandoned by its owners without fuel or provisions in the Strait of Gibraltar, according to local media. 

The Maritime Captaincy for the Port of Malaga told Spanish outlet Sur that the vessel in question, the 5,800 dwt coastal freighter Marine I, was drifting near the Strait and had been without propulsion for 10 days. The crew were reportedly without fuel, water or food, and their ship had been plagued by mechanical issues. 

The Malaga Maritime Authority reported that a tug, the Luz De Mar, was dispatched to take the Marine I in tow and bring it into port at Malaga. The decision was made in order to ensure the safety of the ship and the crew, accord to Sur. 

The Marine I (IMO 9007001) is a freighter built in 1994, and is crewed by 17 seafarers from Azerbaijan, Egypt, Ghana, Montenegro, Nigeria and Ukraine, according to the International Transport Workers' Federation (ITF). Per the ITF's abandonment database, the crewmembers were owed two months of back pay. The owner is based in the UAE, and it also controls another ship, the Sundry (IMO 9045651). This second freighter - like Marine I - has an extensive history of deficiencies.

Top image: Marine I (file image courtesy Cengiz Tokgoz / VesselFinder)

 

Study Finds Major Drop in Ship Sulfur Emissions Following IMO Regulations

containership emitting smoke
Study finds compliance with the IMO 2020 regulation reducing sulfur emissions (iStock)

Published Dec 2, 2025 6:25 PM by The Maritime Executive

 

An academic team led by researchers at the UK’s National Centre for Atmospheric Science completed a first in-depth study looking at sulfur emissions at sea and found “fairly good compliance” with the IMO regulations introduced in 2020. The group looked at compliance both in the European Sulfur Emission Control Areas (SECAs) and ships in the open ocean.

The team found that the average sulfur content in ship fuel dropped nearly tenfold in open ocean areas following the International Maritime Organization’s 2020 regulation, which capped sulfur content in marine fuel at 0.5 percent. Before the change, many ships exceeded the previous 3.5 percent limit. After 2020, they reported that only a small number of ships were found to breach the new standard.

In European Sulfur Emission Control Areas (SECAs), such as the English Channel and the Port of Tyne, sulfur levels were even lower. They said it was well below the stricter 0.1 percent limit, and interestingly, ports outside these zones, like Valencia in Spain, also showed low sulfur levels. They said this was likely due to the European Union’s rules, which also require cleaner fuel when ships are docked for extended periods.

The research, published in Environmental Science: Atmospheres, used aircraft and ground-based instruments to measure sulfur dioxide and nitrogen oxides emitted by ships in the North-East Atlantic and European coastal waters between 2019 and 2023. They noted that this was the first study to use aircraft-based measurements and predictions from the Ship Traffic Emission Assessment Model (STEAM3) to assess ship emissions outside of sulfur control zones since the 2020 regulation came into effect. 

The use of aircraft was a critical component, as the regulations are different in ports and inland waterways compared to the open ocean. The authors said that an aircraft was the only way to get the open ocean measurements. 

While the findings support the widely held view that ships now emit around seven times less sulfur than before the rule change, they noted that compliance is far from universal.

“It’s a big reduction, largely in line with the change in regulations,” said Professor James Lee, an atmospheric chemist at NCAS and the University of York. 

However, the research found that in the open ocean, five ships out of 78 breached the 0.5 percent sulfur content limit in 2021 and 2022. The researchers noted that their project had a limited sample size, which made it difficult to draw any conclusions about what might cause a ship to breach the limit, e.g. its age or its tonnage.

“That’s quite a substantial proportion of the observed fleet,” noted Professor Hugh Coe, atmospheric composition research scientist at NCAS and the University of Manchester. “While it’s reasonable to assume the fleet’s average is below the 0.5 percent limit, there could be a significant number of outlier ships breaching that limit, potentially having a large effect on local air quality.”

The research said that more measurements would be needed to investigate the cause of the outlier ships. They also recommended that policymakers keep a careful eye on the ships and the challenges to introduce alternative fuels. They said it is important to make sure that any change that might be beneficial from a carbon reduction point of view does not have unexpected and adverse air quality implications.